An Abscopal Effect on Lung Metastases in Canine Mammary Cancer Patients Induced by Neoadjuvant Intratumoral Immunotherapy with Cowpea Mosaic Virus Nanoparticles and Anti-Canine PD-1

Neoadjuvant intratumoral (IT) therapy could amplify the weak responses to checkpoint blockade therapy observed in breast cancer (BC). In this study, we administered neoadjuvant IT anti-canine PD-1 therapy (IT acPD-1) alone or combined with IT cowpea mosaic virus therapy (IT CPMV/acPD-1) to companion...

Descripción completa

Detalles Bibliográficos
Autores: Sergent, Petra, Pinto-Cárdenas, Juan Carlos, Arreguin Carrillo, Adhara Jaciel, Luna Dávalos, Daniel, González Pérez, Marisa Daniela, Mendoza Lechuga, Dora Alicia, Alonso Miguel, Daniel, Schaafsma, Evelien, Jiménez Cuarenta, Abigail, Cárdenas Muñoz, Diana, Zarabanda, Yuliana, Palisoul, Scott M., Lewis, Petra J., Kolling IV, Fred W., Affonso de Oliveira, Jessica Fernanda, Steinmetz, Nicole F., Rothstein, Jay L., Lines, Louise, Noelle, Randolph J., Fiering, Steven, Arias Pulido, Hugo
Tipo de recurso: artículo
Fecha de publicación:2024
País:España
Institución:Universidad Complutense de Madrid (UCM)
Repositorio:Docta Complutense
Idioma:inglés
OAI Identifier:oai:docta.ucm.es:20.500.14352/108215
Acceso en línea:https://hdl.handle.net/20.500.14352/108215
Access Level:acceso abierto
Palabra clave:636.09:616-006.04
Abscopal effect
Anti-canine PD-1
Canine NanoString array
Canine mammary carcinomas
Cowpea mosaic virus
Immune cells
Intratumoral injections
Lung metastasis
Plant virus
Tumor microenvironment
Veterinaria
3109 Ciencias Veterinarias
Descripción
Sumario:Neoadjuvant intratumoral (IT) therapy could amplify the weak responses to checkpoint blockade therapy observed in breast cancer (BC). In this study, we administered neoadjuvant IT anti-canine PD-1 therapy (IT acPD-1) alone or combined with IT cowpea mosaic virus therapy (IT CPMV/acPD-1) to companion dogs diagnosed with canine mammary cancer (CMC), a spontaneous tumor resembling human BC. CMC patients treated weekly with acPD-1 (n = 3) or CPMV/acPD-1 (n = 3) for four weeks or with CPMV/acPD-1 (n = 3 patients not candidates for surgery) for up to 11 weeks did not experience immune-related adverse events. We found that acPD-1 and CPMV/acPD-1 injections resulted in tumor control and a reduction in injected tumors in all patients and in noninjected tumors located in the ipsilateral and contralateral mammary chains of treated dogs. In two metastatic CMC patients, CPMV/acPD-1 treatments resulted in the control and reduction of established lung metastases. CPMV/acPD-1 treatments were associated with altered gene expression related to TLR1-4 signaling and complement pathways. These novel therapies could be effective for CMC patients. Owing to the extensive similarities between CMC and human BC, IT CPMV combined with approved anti-PD-1 therapies could be a novel and effective immunotherapy to treat local BC and suppress metastatic BC.

Similares en LA Referencia